anonymous
Guest
anonymous
Guest
Not sure how we are going to pull this off? Our fibrosis data suck. Try convincing the endos with that data. Plus hiring is slow as heck
Not launching w endos and we don’t have approval yet so how is is slow? Do tellNot sure how we are going to pull this off? Our fibrosis data suck. Try convincing the endos with that data. Plus hiring is slow as heck
They’re hiring outside people who have no idea how to get the drug through with a complicated PA. And no history of all the shortages that happened. Good luck!This fall launch has disaster written all over it
Do we ACTUALLY have confirmation layoffs are comingOh I have a great idea!! Let’s hire a new sales force right before massive layoffs.
In our region, sounds like almost all senior-level Novo reps were hired. Do you not think other companies deal with the PA process? Some products are actually much more complicated to get covered than ours.They’re hiring outside people who have no idea how to get the drug through with a complicated PA. And no history of all the shortages that happened. Good luck!
You people do realize that the new indication will have nothing to do with diabetes/weight loss, therefore your proprietary “PA process“ wins you so heavily covet will have no bearing right? This entire thread has proven NN right in the decision to not promote from within for this expansion. For those that are internal candidates that made the cut, disregard all of your prior experience with the molecule and pretend you didn’t have to fight tooth and nail to get it through MC.In our region, sounds like almost all senior-level Novo reps were hired. Do you not think other companies deal with the PA process? Some products are actually much more complicated to get covered than ours.
Like the CCS sales force right? Trying to get W for pts, in a cardiology office. The PA process is just insaneYou people do realize that the new indication will have nothing to do with diabetes/weight loss, therefore your proprietary “PA process“ wins you so heavily covet will have no bearing right? This entire thread has proven NN right in the decision to not promote from within for this expansion. For those that are internal candidates that made the cut, disregard all of your prior experience with the molecule and pretend you didn’t have to fight tooth and nail to get it through MC.
MASH is an entirely separate indication not tied to weight.Like the CCS sales force right? Trying to get W for pts, in a cardiology office. The PA process is just insane
Oh yeah it’s so easy. And assuming it is a primary indication (which no one knows yet because the FDA has not approved the label), I’m sure insurance companies won’t implement crazy documentation to prove MASH at all, right? I mean the doc will just have to code for MASH and it’ll sail through! It’ll be smooth as butter!MASH is an entirely separate indication not tied to weight.
CV is tied to weight. Both must be coded on the PA for approval.
It’s almost like launching a new drug if you will.
Insurance companies will not want to pay for this drug. They will put all sorts of roadblocks up to get approval. Previous poster really has no clue on the lengths and hoops insurance companies make offices go through to get approval for 6 monthsOh yeah it’s so easy. And assuming it is a primary indication (which no one knows yet because the FDA has not approved the label), I’m sure insurance companies won’t implement crazy documentation to prove MASH at all, right? I mean the doc will just have to code for MASH and it’ll sail through! It’ll be smooth as butter!
Impact MeasuresName 1 thing at Novo that ISN'T a shitshow?
Ready for what? To go out and talk about the disease state?Next Monday is the official start date. Everyone ready?
You can’t count your chickens yet. Do you remember what happened w the Tresiba launch? We got trained on Tresiba in Vegas expecting to get the indication and then we got a big fat Nope from the FDA…. We didn’t launch until 2 years laterWhy would we fail to get the MASH indication, seems very likely that we will?